Dossier
SonoThera
Coverage of SonoThera in the Nexus archive.
Duchenne muscular dystrophytopic1Eric Olsonperson1Jeffrey Chamberlainperson1UT-Southwestern Medical Centerorganization1University of Washingtonorganization1gene therapytopic1ultrasoundtopic1Novartisorganization1molecular glue strategytopic1Enlivenorganization1leukemia drugtopic1Medicareorganization1GLP-1 medicinestopic1Part D redesigntopic1
- STAT+: Can ultrasound unlock the power of gene therapy? A startup makes big claims
Sonothera, a California startup, claims its ultrasound technology could treat Duchenne muscular dystrophy and other genetic diseases, though it lacks clinical data. Animal study results presented by the company have sparked skepticism from experts like Eric Olson and Jeffrey Chamberlain, who question the feasibility of the claims.
- STAT+: Novartis doubles down on molecular glue strategy
Novartis is expanding its molecular glue strategy, Enliven's leukemia drug shows encouraging early data, and SonoThera raised $125 million for an ultrasound-based gene delivery approach. Medicare drug spending is rising faster than expected due to increased GLP-1 medicine use and the Democrats’ Part D redesign.